美通社

2024-08-05 10:34

DKSH and Kyowa Kirin Forge Strategic Partnership Across Asia-Pacific

DKSH has signed a strategic business partnership with Kyowa Kirin, a Japan-based global specialty pharmaceutical company, to provide comprehensive services for their specialty drugs in South Korea, Taiwan region, Singapore, Thailand, Malaysia and Hong Kong & Macau SAR. With DKSH's expertise, distribution networks, and strong commercial capabilities, this partnership further enhances patient care and accessibility in the region.

SINGAPORE, Aug. 5, 2024 /PRNewswire/ -- DKSH Business Unit Healthcare, a Strategic Healthcare Solutions Partner and leading provider of Market Expansion Services for pharmaceutical, over-the-counter (OTC), consumer health and medical device companies, enters a partnership with Kyowa Kirin Co., Ltd. (Kyowa Kirin, TSE:4151, President and CEO: Masashi Miyamoto), a Japan-based global specialty pharmaceutical company, in line with Kyowa Kirin's announced plans to transform its business in Asia-Pacific. The scope of the partnership covers a promotion and distribution agreement for commercial rights of Kyowa Kirin's established medicines portfolio in South Korea, Taiwan region, Singapore, Thailand, Malaysia and Hong Kong & Macau SAR as well as global products -- Crysvita® in in Singapore, Thailand, Malaysia and Hong Kong & Macau SAR and Poteligeo ® in Singapore.

Recognized for offering a full range of integrated solutions to support sustainable growth for client partners, DKSH has been chosen by Kyowa Kirin as its strategic partner to implement a full agency alliance business model that delivers end-to-end healthcare solutions prioritizing healthcare access to patients. With DKSH's deep expertise in nephrology, robust distribution networks, and strong commercial capabilities – this collaboration reinforces a significant step forward in continuing patient care and accessibility in the region.

"We are very confident about this new journey with DKSH", stated Abdul Mullick, Ph.D., Chief International Business Officer (CIBO), Kyowa Kirin. "Given DKSH's proven healthcare expertise and commercial strength across Southeast Asia and North Asia, we are convinced we have chosen the right business partner to continue serving our patients, taking care of our employees and making people smile."

Bijay Singh, Global Head Business Unit Healthcare, Member of the Executive Committee, DKSH, added: "We are thrilled to embark on this brand new partnership with Kyowa Kirin, especially as they chose DKSH as a regional partner across 6 markets. This collaboration reflects DKSH's commitment to driving growth for our clients while at the same time pursuing our mission of providing better healthcare to all patients in our markets. By combining our expertise and resources with Kyowa Kirin's excellent brands, we are confident we can provide a more cost-effective yet high quality commercial access solution that provides outstanding patient outcomes and customer service."

About Kyowa Kirin

Kyowa Kirin aims to discover novel medicines with life-changing value. As a Japan-based Global Specialty Pharmaceutical Company, Kyowa Kirin has invested in drug discovery and biotechnology innovation for more than 70 years and is currently working to engineer the next generation of antibodies and cell and gene therapies with the potential to help patients affected by a severe or rare disease. A shared commitment to its values, to sustainable growth, and to making people smile unites us across its four regions – Japan, Asia Pacific, North America, and EMEA/International. www.kyowakirin.com

About DKSH Holding Ltd.

DKSH's purpose is to enrich people's lives. For almost 160 years, DKSH has been delivering growth for companies in Asia and beyond across its Business Units Healthcare, Consumer Goods, Performance Materials, and Technology. As a leading Market Expansion Services provider, DKSH offers sourcing, market insights, marketing and sales, eCommerce, distribution and logistics as well as after-sales ser-vices. DKSH is a participant of the United Nations Global Compact and adheres to its principles-based approach to responsible business. Listed on the SIX Swiss Exchange, DKSH operates in 36 markets with 29,040 specialists, generating net sales of CHF 11.1 billion in 2023. As a strategic healthcare business partner, DKSH Business Unit Healthcare distributes and commercializes pharmaceuticals, consumer health, and over-the-counter products as well as medical devices. With around 8,140 specialists, the Healthcare Business Unit generated net sales of CHF 5.6 billion in 2023. www.dksh.com/hec

source: DKSH Healthcare

送禮活動浪接浪!想緊貼著數活動消息?即Like etnet Facebook專頁!► 立即讚好

人氣文章
最近7天
1
高息定存 | 6個月港元定存3.8厘新高,188日快閃優惠3.68厘
2
高息定存 | 富邦推快閃定存優惠3個月3.9厘,華僑188日3.68厘
3
港股 | 蕭猷華:內地AI發展迅速,阿里巴巴股價看俏
4
港股 | 蕭猷華:恒指料退守至18600點,宜逢低吸納
5
內銀股 | 人行再提擇機減息降準,內銀獲中金唱好,應該點部署?
6
大國博弈 | 【FOCUS】騰訊商湯寧德重挫,CMC清單劍指軍民融合
7
加州山火 | 【FOCUS】洛杉磯烈火焚城,天災背後藏人禍
8
新股掛牌 | 布魯可首日掛牌升41%,每手賺7395元
9
高息定存 | 一周高息合集,銀行高息搶存,富邦1個月4.88厘,華僑1年期3.6厘
10
高息定存 | 一周高息合集,恒生1個月定存4厘,工銀亞洲3個月最高5厘
11
英偉達 | DeepSeek衝擊AI晶片行業結構 英偉達暴跌仍未急抄底
12
高息定存 | 渣打特選客6個月3.48厘,建行亞洲推1個月6.18厘高息吸客
13
高息定存 | 花旗3個月港元定存息加至4厘,信銀國際3.88厘
14
一本萬利 | 2025年的五個「勿」(有片)
15
互聯支付 | 黃俊碩:轉數快與IBPS互聯支付所產生的發展契機
16
環球央行 | 歐洲央行宣布再次減息0.25厘,符合市場預期
17
高息定存 | 一周高息合集,銀行高息吸客,低門檻10萬享6.18厘,3個月最高5厘
18
港股 | 蕭猷華:恒指春節前目標21500點
19
財政預算案2025 | 羅兵咸料本財年財赤948億,財政儲備降至紀錄新低
20
專訪|洪灝:美股更大跌幅在前面,恐需習慣4%通脹(有片)
21
神州經脈 | 基金賣股票據報受限,滬指連跌四日,人行穩匯率
22
習近平應約與特朗普通電話,特:冀盡快與習見面
23
加州山火 | 美國洛杉磯大火失控,被迫撤離人數增至18萬
24
【FOCUS】去年貿易順差破紀錄,中國擴消費增緊迫感
25
【FOCUS】侵侵就職倒數一周,美元及油價劇本臨揭盅
26
加州山火造成超500億美元損失,大量房主未買保險
27
賣地計劃 | 政府今季推一幅東涌住宅地涉745伙,全年供應不達標
28
高息定存 | 一周高息合集,部分銀行逆市加息,南商3個月加至3.8厘
29
雷賢達觀點 | 香港篇:恒指年波幅料六千點,港須全面融入大灣區
30
新世界 | 摩通:新世界若債務違約或打開行業「潘朵拉盒子」
專業版
HV2
精裝版
SV2
串流版
IQ 登入
強化版
TQ
強化版
MQ

【etnet 30周年】多重慶祝活動一浪接一浪,好禮連環賞!

【蛇年行大運 新年好賞「飾」】etnet賞太歲開運趨吉避凶神器

etnet榮獲HKEX Awards 2023 「最佳證券數據供應商」大獎

貨幣攻略

大國博弈

說說心理話

聖誕新年特輯

Watch Trends 2024

北上食買玩

Art Month 2024

秋天養生食療

山今養生智慧

輕鬆護老